Please assess the completion status of the following clinical trial:

Trial Title: Cervical Ripening Balloon in Induction of Labour at Term

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women aged 21 - 40 years old~* Singleton pregnancy with no major fetal anomaly~* Planned induction of labour at 37+0 weeks to 41+6 weeks gestation~* Vaginal delivery is appropriate~* Patient able to give informed consent to participate in the trial~Exclusion Criteria:~* Spontaneous labour at start of planned induction~* Bishop score \<6 and cervical dilatation \>=3 cm at start of induction~* Confirmed rupture of membrane~* Abnormal CTG at start of induction~* Caesarean section delivery is indicated~* Scarred uterus such as previous caesarean section~* Malpresentation in labour~* Latex allergy, severe asthma and glaucoma~* Patient withdraw consent to participate in the trial

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Cervical Ripening Balloon (Type: EXPERIMENTAL): Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
- Prostin (Type: ACTIVE_COMPARATOR): Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.

Based on this trial design, predict the completion outcome and termination type (if applicable).